This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin (INTERCEPTOR)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
MARCO MERLANO, Gruppo Oncologico del Nord-Ovest
ClinicalTrials.gov Identifier:
NCT00999700
First received: October 16, 2009
Last updated: February 27, 2017
Last verified: February 2017
  Purpose
A phase III trial of induction chemotherapy followed by definitive radiotherapy plus Cetuximab versus chemoradiation in unresectable, locally advanced, squamous cell carcinoma of the head and neck (HNC).

Condition Intervention Phase
Squamous Cell Carcinoma of the Head and Neck Drug: docetaxel - cisplatin - 5-fluorouracil Radiation: radiotherapy Drug: cetuximab Drug: cisplatin Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin

Resource links provided by NLM:


Further study details as provided by MARCO MERLANO, Gruppo Oncologico del Nord-Ovest:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • Incidence of acute and late toxicities in the two arms [ Time Frame: 5 years ]
  • Progression free survival [ Time Frame: 5 years ]
  • Locoregional control [ Time Frame: 5 years ]
  • Response rate [ Time Frame: 5 years ]

Estimated Enrollment: 282
Study Start Date: September 2009
Estimated Study Completion Date: December 2021
Estimated Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ARM A
Induction chemotherapy: TCF (Vermorken, N Eng J Med 2007) Definitive treatment: RT + C-mab (Bonner, N Eng J Med 2006)
Drug: docetaxel - cisplatin - 5-fluorouracil
docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
Radiation: radiotherapy

Conformal radiotherapy or IMRT should be employed.

Standard radiotherapy:

Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.

Drug: cetuximab
400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
Active Comparator: ARM B
RT + Cddp (RTOG, Adelstein, J Clin Oncol 2003)
Drug: cisplatin
Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
Radiation: radiotherapy

Conformal radiotherapy or IMRT should be employed.

Standard radiotherapy:

Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated.


Detailed Description:
The objective of this trial is to determine whether Cetuximab and radiation preceded by an induction chemotherapy, may be superior to an established chemoradiation program for HNC (RTOG regimen, Adelstein DJ J.Clin.Oncol. 2003;21:92-98).
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • > 18 years of age
  • Histologically or cytologically confirmed diagnosis of HNSCC
  • Stage III/IV, not suitable for surgery (definitive cure rate improbable, technically unresectable or medical contraindication for surgery)
  • At least one uni-dimensional measurable lesion either by CT scan or MRI
  • Signed written informed consents prior to beginning protocol

Specific procedures:

  • Tumor tissue available for immunohistochemical staining of EGFR expression and HPV
  • Life expectancy of > 3 months at study entry
  • ECOG Performance Status of <2 at study entry.
  • Effective contraception if risk of conception exists.
  • Neutrophils > 2.0/mm³, platelet count > 100,000/mm³, and hemoglobin > 10 g/dl
  • Normal liver function
  • Serum creatinine > 1.25 x ULN and/or creatinine clearance > 60 ml/min

Exclusion Criteria:

  • Prior systemic chemotherapy and/or radiotherapy
  • Known peripheral neuropathy > grade 2 NCI-CTC version 3.0
  • Known chronic heart failure
  • Prior surgery, excluding prior diagnostic biopsy
  • Known drug abuse
  • Active uncontrolled infection
  • Other concomitant anticancer therapy
  • Distant metastasis
  • Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy not indicated in the study protocol
  • Clinically relevant coronary artery disease or history of a myocardial infarction within the last 12 months before study entry
  • Medical or psychological condition that would not permit the patient to complete the trial or sign informed consent
  • Nasopharyngeal carcinoma WHO type II or III
  • Known allergic reaction against any of the components of the treatment
  • Pregnancy (absence confirmed by beta-HCG test) or lactation period
  • Any prior or on-going investigational medication
  • Previous or current malignancy except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00999700

Locations
Italy
Ospedale Civile Ss. Antonio E Biagio
Alessandria, Italy
Ausl Della Valle D' Aosta
Aosta, Italy
Policlinico S. Orsola-Malpighi
Bologna, Italy
Asl 8 - Ospedale Businco
Cagliari, Italy
A.S.O. S. Croce E Carle
Cuneo, Italy, 12100
Irccs - Aou S. Martino - Oncology
Genoa, Italy
Irccs - Aou San Martino - Radiotherapy
Genoa, Italy
Asl 3 Genovese
Genova, Italy
E.O. Ospedali Galliera
Genova, Italy
Azienda Ospedaliera Villa Scassi - Asl3
Italy, Italy
Istituto Nazionale Dei Tumori
Milano, Italy
Azienda Ospedaliero Universitaria Di Modena
Modena, Italy
Ospedale S. Giacomo
Novi Ligure (al), Italy
Azienda Ospedaliero-Universitaria Di Parma
Parma, Italy
Azienda Ospedaliera Ospedali Riuniti Di Fano
Pesaro, Italy
Arcispedale S. Maria Nuova
Reggio Emilia, Italy
Irccs Centro Di Riferimento Oncologico Di Basilicata (Crob)
Rionero in Vulture (pz), Italy
Ospedale S. Filippo Neri
Roma, Italy
Ospedale S. Paolo
Savona, Italy
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino Torino (to)
Turin, Italy
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino
Turin, Italy
Sponsors and Collaborators
Gruppo Oncologico del Nord-Ovest
Investigators
Principal Investigator: MARCO MERLANO, MD ASCO, ESMO, AIOM, G.O.N.O.
  More Information

Additional Information:
Publications:
Responsible Party: MARCO MERLANO, MD, Gruppo Oncologico del Nord-Ovest
ClinicalTrials.gov Identifier: NCT00999700     History of Changes
Other Study ID Numbers: EUDRACT NUMBER 2009-013402-14
Study First Received: October 16, 2009
Last Updated: February 27, 2017

Keywords provided by MARCO MERLANO, Gruppo Oncologico del Nord-Ovest:
Locally advanced HNSCC
Chemo-radiation
Induction chemotherapy
Stage III/IV
Unresectable disease

Additional relevant MeSH terms:
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Docetaxel
Cisplatin
Cetuximab
Fluorouracil
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2017